Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Talmapimod (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 28 Oct 2005 New trial record.